Romosozumab

Latest news

Tag

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially redu

Mar 10, 2026

Clinical Updates

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

This review evaluates the LIDA trial’s findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.

Mar 9, 2026

Diabetes & Endocrinology

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis

The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injec

Feb 24, 2026